Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Stakeholder engagement sits at the center of this dementia and brain health question.
Stakeholder engagement forums are fundamentally reshaping how Alzheimer’s disease research priorities get determined, shifting focus from researcher preferences alone to collaborative decisions that reflect the actual needs of patients, families, and communities. These forums bring together diverse voices—patients living with Alzheimer’s, caregivers navigating daily challenges, clinicians, neuroscientists, funding agencies, and industry representatives—to collectively identify which research questions matter most.
For example, when the National Institute on Aging expanded its stakeholder consultation process in recent years, it discovered that many families prioritized research on early detection and lifestyle interventions over purely pharmaceutical approaches, a finding that directly influenced which grant proposals received funding priority. The impact of these engagement forums extends beyond symbolic inclusion; they actively determine research direction, funding allocation, and the metrics by which success gets measured. Rather than research agendas flowing top-down from academic institutions and pharmaceutical companies, stakeholder forums create a two-way dialogue that ensures invested parties have genuine influence over the science being pursued.
Table of Contents
- How Do Stakeholder Forums Influence Research Direction and Priorities?
- The Tension Between Patient Priorities and Scientific Feasibility
- Who Participates in These Forums and What Perspectives They Bring
- How Funding Agencies Use Forum Input to Allocate Research Resources
- Challenges in Maintaining Authentic Representation and Avoiding Tokenism
- Real-World Example: The Stakeholder Engagement Process Behind NIH Research Priorities
- The Future of Stakeholder Engagement in Alzheimer’s Research
- Conclusion
How Do Stakeholder Forums Influence Research Direction and Priorities?
Stakeholder engagement forums influence research priorities through structured processes that systematically gather input on what questions researchers should tackle first. These forums typically operate through multiple channels: roundtable discussions, online surveys, focus groups with specific stakeholder populations, and formal advisory board positions held by patient and caregiver representatives. When the Alzheimer’s Association convened its annual stakeholder summit in partnership with the NIH, participant feedback directly shaped the 2024-2025 research funding roadmap, with input from 300+ stakeholders identifying early cognitive decline and prevention in at-risk populations as higher priorities than previously funded clinical trials alone.
The mechanism works because funders and researchers take these inputs seriously—they’re not merely listening but implementing changes in response. When a consortium of caregiver organizations emphasized the need for research on behavioral interventions in later-stage disease, major research institutions began redirecting project proposals toward that area. However, a limitation exists: stakeholder forums tend to overrepresent organized patient advocacy groups and underrepresent quieter populations, such as rural caregivers, racial minorities underrepresented in research, and people with early-onset Alzheimer’s. This skew can inadvertently perpetuate existing research gaps rather than address them comprehensively.
The Tension Between Patient Priorities and Scientific Feasibility
Stakeholder engagement forums reveal a persistent tension between what patients and families most desperately want researched and what neuroscience can realistically deliver within near-term timeframes. Patients and caregivers frequently prioritize interventions that reduce burden on daily life—such as better diagnostic tools, behavioral therapies, and symptom management strategies—while researchers and funders often maintain focus on fundamental disease mechanisms and long-term pharmaceutical development. A notable example emerged in 2023 when stakeholder forums highlighted overwhelming demand for research on maintaining cognitive function in the “mild cognitive impairment” stage, yet most funding still flowed to advanced-stage disease and biomarker research that won’t translate to treatments for years.
A significant limitation of stakeholder engagement forums is that they can’t resolve genuine scientific uncertainties through consensus alone. When caregivers collectively advocate for more research on a particular care approach, that advocacy doesn’t necessarily indicate the approach will prove effective under rigorous testing. The forums work best when they inform priority-setting within realistic constraints, not when they attempt to override scientific judgment about what’s actually testable. Additionally, the heavy engagement of well-resourced advocacy organizations can sometimes amplify particular theories—such as emphasis on amyloid-targeting drugs in earlier years—over alternative approaches that might ultimately prove more beneficial but lack organized stakeholder backing.
Who Participates in These Forums and What Perspectives They Bring
Effective stakeholder engagement forums deliberately recruit diverse participants: people in early stages of Alzheimer’s disease (when they can meaningfully participate), adult children caring for parents, spousal caregivers, dementia specialists, gerontologists, biostatisticians, ethicists, nursing home administrators, and representatives from patient advocacy organizations like the Alzheimer’s Association and UsAgainstAlzheimer’s. Each group brings distinct concerns. Family caregivers emphasize practical challenges like managing behavioral symptoms and maintaining quality of life. Researchers highlight technical feasibility and the current state of neuroimaging or biomarker science.
Nursing home administrators raise concerns about implementability of new interventions in real-world care settings. The inclusion of people living with early-stage Alzheimer’s has emerged as transformative, though logistically challenging. These individuals can articulate what concerns them most—memory loss affecting work performance, impacts on relationships, fears about future decline—in ways that organizational advocates sometimes cannot. A forum convened by the Patient-Centered Outcomes Research Institute explicitly recruited people with mild cognitive impairment and early-stage Alzheimer’s as core participants rather than observers, a structural choice that shifted discussions toward preserving independence and quality of life rather than purely survival metrics. One consistent challenge is ensuring genuine diversity in participation; many forums have historically underrepresented participants from lower-income communities, rural areas, and communities of color, potentially biasing research priorities toward concerns of more privileged populations.
How Funding Agencies Use Forum Input to Allocate Research Resources
Funding agencies like the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and private foundations increasingly use stakeholder forum findings as explicit criteria in research funding decisions. When an agency reviews grant proposals, it now commonly asks: Does this research address priorities identified through stakeholder engagement? Does it consider outcomes that matter to patients and families, not just laboratory measures? Some agencies have implemented scoring systems that give weight to research addressing stakeholder-identified priorities, creating real incentive structures for researchers to align with forum conclusions. The practical tradeoff of this approach is that it can slow funding decisions while ensuring alignment but may also miss innovative research directions that stakeholders haven’t yet envisioned.
When the U.S. Alzheimer’s Association and federal partners conducted a comprehensive stakeholder engagement process before releasing 2024 funding priorities, the expanded consultation process delayed the funding announcement by three months compared to previous years but resulted in significantly higher application quality focused on priorities the community actually valued. Furthermore, some researchers worry that excessive stakeholder influence could privilege applied research over basic science investigations that, while not immediately relevant to patients, might ultimately yield breakthrough discoveries. Balancing meaningful stakeholder input with scientific innovation remains an ongoing challenge.
Challenges in Maintaining Authentic Representation and Avoiding Tokenism
A persistent risk in stakeholder engagement forums is tokenism—including patient and caregiver voices in decision-making structures without genuinely empowering them to influence outcomes. Some forums invite patient representatives to advisory boards but structure the process so that decisions are effectively made before stakeholders arrive, with their input treated as feedback rather than genuine partnership. Real representation requires providing stakeholders with information access equal to that of professionals, compensating people for their expertise and time, training stakeholders in technical concepts when necessary, and making transparent how their input actually shaped final decisions. Another limitation stems from the emotional intensity of Alzheimer’s disease research contexts.
When someone has recently lost a family member to Alzheimer’s or is currently caregiving for a person in advanced stages, their advocacy may become understandably urgent and emotionally driven. Forums sometimes struggle to balance this passionate engagement with objective prioritization across the full spectrum of research needs. Warning: some forums have inadvertently become dominated by particular charismatic advocates or organizations with superior resources for mobilizing supporters, creating a false impression of consensus when significant minority perspectives actually exist. For example, forums that appear to strongly favor pharmaceutical approaches may actually reflect the organizing capacity of industry-backed foundations rather than grass-roots preference, while grassroots interest in non-pharmacological interventions remains high but less formally represented.
Real-World Example: The Stakeholder Engagement Process Behind NIH Research Priorities
The National Institute on Aging’s expansion of its stakeholder consultation process offers a concrete example of how these forums shape research direction. In 2022-2023, the NIH conducted extensive engagement including patient panels, caregiver focus groups, clinician advisory meetings, and open public comment periods before releasing updated research priorities for 2024-2028. Input from nearly 500 stakeholders directly influenced decisions to increase funding for research on health equity in dementia care, advance work on cognitive reserve and modifiable risk factors, and expand research on diverse populations previously underrepresented in Alzheimer’s studies.
Specifically, stakeholder input led to a notable shift: previous funding priorities had emphasized neuroscience and biomarker research; the updated priorities gave substantially greater weight to pragmatic outcomes research—studies examining what actually works in real care settings. This wasn’t a rejection of basic science but a rebalancing acknowledging that stakeholders wanted to see research that could more directly improve lives within 5-10 years, not just in 20-year timeframes. The process also revealed significant stakeholder concern about the dominance of amyloid and tau in research focus, prompting the NIH to increase funding for research on vascular contributions to cognitive decline and inflammatory mechanisms—areas that had received proportionally less attention.
The Future of Stakeholder Engagement in Alzheimer’s Research
Stakeholder engagement in research priority-setting is evolving toward more sophisticated and inclusive structures. Emerging approaches include participatory research models where patients and caregivers co-design studies rather than simply providing input on others’ research agendas, digital platforms allowing broader participation beyond in-person meetings in major cities, and deliberate efforts to reach historically marginalized communities including rural populations, people with limited English proficiency, and individuals from lower-income backgrounds. Some organizations are experimenting with “patient-led research networks” where people with cognitive concerns themselves identify research questions and partner with institutions to investigate them.
The field increasingly recognizes that authentic stakeholder engagement requires investment in infrastructure and support—not just good intentions. The future likely involves dedicated funding for patient and caregiver participation itself, training programs to build stakeholder expertise, and accountability mechanisms ensuring that advisory structures translate input into actual decision-making changes. As Alzheimer’s research becomes more focused on prevention and early intervention, stakeholder perspectives will become even more critical, since these research phases require large numbers of cognitively normal people willing to participate and engage communities in understanding why prevention research matters to them.
Conclusion
Stakeholder engagement forums have fundamentally shifted Alzheimer’s research from a purely researcher-driven enterprise to a collaborative endeavor where patients, caregivers, and communities have genuine influence over research direction and priorities. These forums help ensure that research pursued actually addresses the concerns and needs of the people who experience Alzheimer’s disease and care for those affected, rather than relying on assumptions by scientific experts.
The inclusion of diverse stakeholder voices has already demonstrably changed funding patterns, shifted emphasis toward prevention and real-world outcomes, and increased attention to health equity and underrepresented populations in research. Moving forward, the challenge lies in strengthening these engagement structures—ensuring genuine representation rather than tokenism, compensating stakeholders fairly for their expertise, and maintaining accountability between what forums identify as priorities and what research ultimately gets funded and conducted. As Alzheimer’s disease research evolves toward earlier intervention and prevention, stakeholder engagement becomes not just ethically important but practically essential to ensuring research remains connected to the lived experiences and values of the communities it aims to serve.
You Might Also Like
- Lysosomal Function Research Connects Cellular Waste Processing to Alzheimer’s
- Relay Events Unite Athletes and Supporters in Alzheimer’s Fundraising
- Physical Therapy Programs Show Functional Benefits for Alzheimer’s Patients
For more, see Alzheimer’s Association — caregiving.
